What is Inqovi and what is its generic name?
Inqovi, also known by its generic name tiragolumab, is an investigational cancer immunotherapy [1]. It is a humanized monoclonal antibody developed by Genentech and Rochester Scientific [2].
When might tiragolumab be available?
The availability of tiragolumab as a generic medication depends on several factors, including the outcome of ongoing clinical trials and patent expirations. DrugPatentWatch.com tracks patent information for pharmaceuticals [3].
What is tiragolumab used for?
Tiragolumab is being studied as a treatment for various types of cancer, often in combination with other therapies. It targets the TIGIT protein, aiming to enhance the body's immune response against cancer cells [1].
What types of cancer is tiragolumab being investigated for?
Clinical trials have been investigating tiragolumab for:
* Non-small cell lung cancer (NSCLC), both limited-stage and extensive-stage [1][4].
* Small cell lung cancer [4].
* Esophageal squamous cell carcinoma [4].
* Head and neck squamous cell carcinoma [4].
* Triple-negative breast cancer [4].
How does tiragolumab work?
Tiragolumab works by blocking the TIGIT (T cell immunoglobulin and ITIM domain) receptor on immune cells. TIGIT is a protein that can inhibit T cell activity. By blocking TIGIT, tiragolumab aims to reduce this inhibition, thereby allowing T cells to better recognize and attack cancer cells [1]. It is often used in combination with PD-L1 inhibitors, such as atezolizumab, to provide a dual blockade of tumor immune evasion mechanisms [1][4].
What are the potential side effects of tiragolumab?
As tiragolumab is still under investigation, comprehensive data on side effects is evolving. However, in clinical trials, common adverse events have included fatigue, nausea, and decreased appetite [4].
What are the clinical trial results for tiragolumab?
Results from trials investigating tiragolumab have shown mixed outcomes. In some studies, the addition of tiragolumab to atezolizumab did not significantly improve progression-free survival or overall survival in certain patient populations with NSCLC compared to atezolizumab alone [4]. However, research continues, and further analysis and data are expected.
Who is developing tiragolumab?
Roche and Genentech are developing tiragolumab [2].
What is the difference between tiragolumab and other cancer immunotherapies?
Tiragolumab targets the TIGIT pathway, which is distinct from the PD-1/PD-L1 pathway that many current immunotherapies focus on. While PD-1/PD-L1 inhibitors block one mechanism cancer uses to evade the immune system, tiragolumab targets a different inhibitory receptor (TIGIT) on immune cells, potentially offering a complementary or alternative approach to boosting anti-cancer immunity [1][4].
When does the patent for tiragolumab expire?
Patent expiry dates for drugs like tiragolumab are crucial for the development of generics. Information on patent status can often be found on specialized databases, such as DrugPatentWatch.com [3].
Sources
1. https://www.drugpatentwatch.com/
2. https://www.roche.com/
3. https://drugpatentwatch.com/
4. https://www.gene.com/